Bristol-Myers Squibb Company has announced results of new clinical research of its Immuno-Oncology agents – Opdivo and Yervoy – will be presented at the Society for Melanoma Research (SMR) 2015 International Congress in San Francisco, CA from November 18 – 21. Studies to be presented at SMR illustrate Bristol-Myers Squibb’s scientific commitment, through its Immuno-Oncology research, to developing treatment options for patients with advanced melanoma.
Michael Giordano, M.D., senior vice president, head of Development, Oncology, Bristol-Myers Squibb commented, “The new research to be presented at SMR, including long-term overall survival data from two of our clinical trials, reinforces our understanding of the Opdivo + Yervoy Regimen and Opdivo monotherapy in advanced melanoma. We have made significant advancements in expanding the treatment options available for advanced melanoma, and our ongoing development program continues to demonstrate our commitment to exploring the potential of Opdivo and Yervoy across stages of disease and lines of therapy.”
Data to be presented by Bristol-Myers Squibb include:
| |
|
|
|
|
|
|
|
|
Key Presentations
|
|
|
|
Date/Time
|
|
|
|
| |
|
|
|
|
|
|
|
|
Two-Year Survival and Safety Update in Patients (pts) with
|
|
|
|
Poster presentations will be displayed
|
|
|
|
|
Treatment-Naïve Advanced Melanoma (MEL) Receiving
|
|
|
|
throughout the congress during normal
|
|
|
|
|
Nivolumab (NIVO) or Dacarbazine (DTIC) in CheckMate -066
|
|
|
|
congress hours.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Updated Survival, Response and Safety Data in a Phase 1 Dose-Finding
|
|
|
|
Reception and Poster Viewing
|
|
|
|
|
Study (CA209-004) of Concurrent Nivolumab (NIVO)
|
|
|
|
Wednesday, November 18th
|
|
|
|
|
and Ipilimumab (IPI) in Advanced Melanoma
|
|
|
|
7:30 – 9:30 p.m. PST
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
Lunch and Poster Viewing
|
|
|
|
| |
|
|
|
Thursday, November 19th
|
|
|
|
| |
|
|
|
12:30 – 2:00 p.m. PST
|
|
|
|
| |
|
|
|
|
|
|
|
| |
|
|
|
Poster Reception
|
|
|
|
| |
|
|
|
Thursday, November 19th
|
|
|
|
| |
|
|
|
6:00 – 8:00 p.m. PST
|
|
|
|
| |
|
|
|
|
|
|
|
| |
|
|
|
Lunch and Poster Viewing
|
|
|
|
| |
|
|
|
Friday, November 20th
|
|
|
|
| |
|
|
|
12:30 – 2:00 p.m. PST
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
Lunch and Poster Viewing
Saturday, November 21st
12:00 – 1:30 p.m. PST
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
Patient Reported Outcomes (PROs) from a Phase 3 Study of
|
|
|
|
Oral Presentation
|
|
|
|
|
Nivolumab (NIVO) Alone or Combined with Ipilimumab (IPI)
|
|
|
|
Thursday, November, 19th
|
|
|
|
|
versus IPI in Patients with Advanced Melanoma (MEL):
|
|
|
|
11:30 – 11:50 a.m. PST
|
|
|
|
|
CheckMate -067
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
Efficacy and Safety of Nivolumab (NIVO) Monotherapy in the
|
|
|
|
Oral Presentation
|
|
|
|
|
Treatment of Advanced Mucosal Melanoma (MEL)
|
|
|
|
Friday, November 20th
|
|
|
|
| |
|
|
|
9:10 – 9:25 a.m. PST
|
|
|
|
| |
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
Additional Presentations
|
|
|
|
Date/Time
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Health-Related Quality of Life (HRQoL) and Health Care
|
|
|
|
Poster presentations will be displayed
|
|
|
|
|
Resource Use (HCRU) from a Phase 3 Study of Nivolumab
|
|
|
|
throughout the congress during normal
|
|
|
|
|
(NIVO) versus Dacarbazine (DTIC) in Patients (pts) with
|
|
|
|
congress hours.
|
|
|
|
|
Treatment-Naive Advanced Melanoma (MEL): CheckMate -066
|
|
|
|
|
|
|
|
|
|
|
|
|
Reception and Poster Viewing
|
|
|
|
|
Efficacy and Safety of Nivolumab (NIVO) in Patients (pts) with
|
|
|
|
Wednesday, November 18th
|
|
|
|
|
Advanced Melanoma (MEL) Who Were Treated Beyond
|
|
|
|
7:30 – 9:30 p.m. PST
|
|
|
|
|
Progression in CheckMate -066/-067
|
|
|
|
|
|
|
|
|
|
|
|
|
Lunch and Poster Viewing
|
|
|
|
|
Real-World (RW) Clinical and Economic Impact of Adverse
|
|
|
|
Thursday, November 19th
|
|
|
|
|
Events (AEs) Commonly Associated with Interferon (IFN) with
|
|
|
|
12:30 – 2:00 p.m. PST
|
|
|
|
|
Stage III Melanoma (MEL)
|
|
|
|
|
|
|
|
|
|
|
|
|
Poster Reception
|
|
|
|
|
Real-World (RW) Treatment Patterns with Advanced Melanoma
|
|
|
|
Thursday, November 19th
|
|
|
|
|
(MEL) Patients (pts): Results from a multinational, prospective,
|
|
|
|
6:00 – 8:00 p.m. PST
|
|
|
|
|
observational study (IMAGE)
|
|
|
|
|
|
|
|
|
|
|
|
|
Lunch and Poster Viewing
|
|
|
|
|
Long-Term Drug Costs per Life Month and Overall Survival
|
|
|
|
Friday, November 20th
|
|
|
|
|
Associated with First-Line Treatments for Metastatic Melanoma
|
|
|
|
12:30 – 2:00 p.m. PST
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Systemic Review of the Caregiver Burden in Melanoma and
|
|
|
|
Lunch and Poster Viewing
|
|
|
|
|
Renal Cell Carcinoma Within Europe
|
|
|
|
Saturday, November 21st
|
|
|
|
|
|
|
|
|
12:00 – 1:30 p.m. PST
|
|
|
|
|
Comparative Effectiveness Research (CER) of Treatment for
|
|
|
|
|
|
|
|
Advanced Melanoma in Europe Using Existing Real-World Data
|
|
|
|
|
|
|
|
Sources: A Feasibility Assessment
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Long-Term Temporal Trends in Survival Among Danish Patients
|
|
|
|
|
|
|
|
with Advanced Cutaneous Melanoma: A Nationwide Follow-Up Study
|
|
|
|
|
|
|